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Although patent filing is increasing worldwide, it does not follow a uniform growth trend. China and South Korea have 
seen a substantial growth in patent filing as compared to developed nations. Regarding India, the growth is minimal. The 
trend reveals that more patents in India are filed for formulations, dosage forms, combination drugs and mode of delivery. 
New drug discovery has moved away from chemical entities to biological moieties. India, though known for its significant 
contribution to pharmaceutical industry by way of generic drugs is yet to make a meaningful presence in the patent scenario. 
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Introduction 
India is a leading producer of generic medicines 
and caters to most developing nations by providing 
lower priced drug formulations. The Indian 
pharmaceutical industry is also one of the leading 
filers of Abbreviated New Drug Applications 
(ANDA) in the USA and further supplies finished 
formulations to the European region. However, it is 
generally observed that the Indian patent scenario is 
not robust and see a lower number of patent 
applications from the industry despite the tremendous 
growth in terms of market presence. The present study 
is an attempt to highlight the patent filing trends in 
India, with respect to pharmaceutical patents and 
assess the available opportunities to intensifying 
research and generate a larger patent portfolio. 
A global R&D funding forecast study1 has reported 
a growth in R&D funding. An increase in R&D 
investment was observed in Asia, particularly China, 
while an unchanged investment in R&D spending in 
North America indicated a period of stability, security 
and healthy competition across industrial sectors. 
According to Unnikrishnan2, India adopted the patent 
regime in pharmaceutical sector to comply with the 
WTO agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) in 2005. This 
change in patentable subject matter although resulted 
in more prominence to foreign drug makers especially 
in the new and innovative medicine space, the market 
is nevertheless dominated by local companies who 
have gained strength as generic drug manufacturers. 
A report published by Indian Brand Equity 
Foundation (IBEF)3 states that the Indian 
pharmaceutical industry accounts for about 2.4 per 
cent of the global pharmaceutical industry in value 
terms and 10 per cent in volume terms. 
The statistical data published by WIPO4 disclose 
that the number of patent applications filed in India 
has witnessed a steady growth and has plateaued in 
the recent past. Pharmaceutical patents are ranked 
second with respect to the volume of applications but 
is still a fraction of pharmaceutical patents filed 
worldwide. 
A study of the patenting trends in pharmaceuticals 
is important as the industry is focused on 
manufacturing life-saving drugs which are often 
patent protected, providing the innovator an 
opportunity to commercially exploit their research 
products without any competitor product during the 
life-time of the patent. The Indian companies though, 
are leaders in the generic drug industry, wherein they 
enter the market after the life time of a patent, but it 
still provides them an opportunity to exploit the 
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market by adding certain unique features to the drug 
product and exercise monopoly over that particular 
feature. An economical process for making a new 
drug formulation, change in dosage regimen and new 
form of drug delivery are all examples of patents that 
bestows commercial advantage to a patent holder ever 
after the expiry of the innovator patent. 
Objective of the study 
To understand the patent filing trends in India with 
reference to pharmaceutical industry.  
Methodology 
Patent applications and publication data worldwide 
in pharmaceutical science was reviewed to understand 
the recent trends in terms of growth and implication 
of international treaties such as TRIPS and related 
changes in national laws to be compliant with TRIPS. 
The trends were examined from the data for a two-
decade period (1997-2016). The period coincided 
with that of India signing the Patent Co-operation 
Treaty (PCT) and TRIPS agreement coming into 
effect. The patent landscape in India with reference to 
change in Patent Act that allowed product patents in 
pharmaceutics in 2005 was studied to understand the 
growth and pattern of patent applications. 
The Indian patent database was accessed at the 
Indian Patent Office website to understand the Indian 
scenario while WIPO (World Intellectual Property 
Organization) website was accessed to determine 
worldwide trends in filing of patent applications. 
Additionally, Thomson Innovation (now known as 
Derwent Innovation) was used to map and analyse the 
trends observed in patent filing in various countries 
across the world and the different sub-areas in 
pharmaceutical industry. 
Analysis 
Patent filings worldwide have grown substantially 
since the early 1990s. A number of new chemical 
entities to treat a new wave of disease conditions were 
developed during the 1980s to mid-1990s. Most of 
these product patents have since expired and a range 
biological drugs are now being developed and 
patented. With a large amount of work having been 
conducted in the last three to four decades, there is a 
general perception that new chemical entities are less 
likely to be discovered or patented and focus has 
shifted to biological entities and formulations. 
International scenario 
As per trends observed, pharmaceutical patents that 
topped the filings and grant across the world earlier 
has shown a decline while computer technology and 
electrical machinery accounted for maximum number 
of patent applications filed in the last decade. These 
two fields have shown substantial growth in the recent 
past. Other industries that have observed a rapid rise 
in patent filings are food chemistry, automobiles and 
telecommunications industry. Pharmaceutical industry 
however, is still among the top five industries that 
witnesses large research activity and patent 
applications. USA, China and Europe account for 
more than half the pharmaceutical patents filed 
worldwide in 2015 as depicted in Figure 1. 
Global patent trends 
The quantum of patent applications filed over the 
last few years disclose that although the number of 
patents filed worldwide grew in numbers, the rate of 
growth has declined. The developed countries are 
growing slower than some of the developing nations. 
The trend was similarly observed in the 
pharmaceutical industry. A slower growth has been 
observed in the last decade partly due to the costs 
involved in patent filing, maintenance and world 
economic scenario. The dearth of new blockbuster 
drugs too has contributed to this trend.  
A recent report on R&D expenditure endorses the 
view that research expenditure worldwide has reduced 
in some parts while it has increased in other parts of 
the world. Over the last several decades, global 
pharmaceutical companies based in the western world 
have led in research expenditure worldwide but in the 
last decade or so, a downward shift has been 
observed. Various factors such as worldwide 
economic slowdown, strengthening of regulatory laws 
and entry of generic players have contributed to this 
reduction. Other factors that have influenced the 
research investments are consumer resistance to high 
priced drugs and lack of a strong pipeline of new 
drugs1. The new drug pipeline has been found to be 
vastly reduced for synthetic chemical molecules and 
the focus has shifted to biological molecules which 
show therapeutic effects. 
The patents filed disclose a focus on smaller projects 
and quick results. Process improvements, newer and 
improved products form a significant part  
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of the patent landscape. The goal is to achieve a 
commercial gain in as small time frame as possible.  
The worldwide research expenditure trend is shown 
in Table 1. 
Patent filing and publication 
To understand the filing phenomena, a search was 
conducted in Thomson Innovation database using 
WIPO's International Patent Classification (IPC) in 
the area of pharmaceutics using the classification code 
A61K (PREPARATIONS FOR MEDICAL, 
DENTAL, OR TOILET PURPOSES) that 
encompasses the pharmaceutical industry. Other 
smaller sections in the classification code in related 
areas were not included to avoid ambiguity of data as 
there could be overlap of other technology areas as 
well. Table 2 reveals the filing and publication trend 
in the last two decades. 
Patent applications were filed largely by multinational 
companies who have a relatively greater R&D spend. 
Figure 2 depicts the list of top ten companies. 
 
Fig. 1—Worldwide pharmaceutical patent filing trend (2010-15) 
Source: Worldwide Innovation Filing Trends 1995-2015;Aug 2015, Gridlogics, Published Online, PP.6  
(https://patseer.com/2015/08/worldwide-innovation-filing-trends-1995-2015/) 
 
Table 1—Share of total global R&D spending 
Region /Country 2014 2015 2016 
North America 29.1% 28.5% 28.4% 
U.S.A. 26.9% 26.4% 26.4% 
Asia 40.2% 41.2% 41.8% 
China 19.1% 19.8% 20.4% 
Europe  21.5% 21.3% 21.0% 
South America 2.8% 2.6% 2.6% 
(Source: 2016 Global R&D Forecast Funding, 2016) 
 
 
Country code Country 
BR Brazil 
IN India 
CA Canada 
AU Australia 
KR S Korea 
EP Europe 
JP Japan 
WO PCT 
US USA 
CN China 
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A further analysis of the patent filings during the 
two decades reveal a growth in number of filings 
despite any significant drug discovery. Although the 
drug pipeline was shrinking, the industry focussed on 
extending the patent life of marketed products by way 
of new dosages, new salts with improved efficacy and 
polymorphs along with new biological entities. An 
upsurge in combination patents has been observed, 
wherein drugs providing synergy were combined to 
yield improved results. The generic pharmaceutical 
companies made a substantial contribution to the 
increase in number of patents filed and published. 
It has been observed that patent applications 
initially increased towards the turn of the last century 
as disclosed in Figure 3. The scenario however 
changed in the last decade when the number of patent 
filings reduced indicating a slowdown despite the 
number of filings increasing from Asian countries 
such as China and S Korea, while more patents were 
published and granted.  
Pharmaceutical industry in India 
India changed its Patent Act in 1971 to exclude 
product patents in pharmaceutical and food sectors. 
This was primarily incorporated to provide a boost to 
domestic industries and safeguard health and food 
needs of the population at large. However, when India 
signed the TRIPS agreement, this had to change.  
The agreement on Trade Related Aspects of 
Intellectual Property Rights (TRIPS) is an 
international agreement administered by the World 
Trade Organisation (WTO) that sets down minimum 
standards for intellectual property (IP) regulation and 
came into force on 1stJanuary 1995. This introduced 
intellectual property law into the international trading 
system for the first time. In 2001, a further meeting 
was held in Doha, to address the concerns of 
developing countries and provide certain safeguards 
to protect national interests including compulsory 
licensing. 
The member countries were provided adequate 
time to amend their local laws. The developing 
countries including India were allowed to implement 
the regulation by January 1, 2005, thus providing a 
period of additional ten years. It was agreed that 
although TRIPS agreement provides scope for its 
members to implement the provisions and achieve a 
balance to cater to matters of national interests such as 
public health, epidemics etc. members could not 
Table 2—Patents published under A61K 
Period Number of  
patents filed 
Number of  
patents published 
1997-2006 2,101,208 1,752,941 
2007-2016 1,961,218 2,596,673 
 
 
Fig. 2—Top ten global patent applicants (1997-2016) 
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discriminate between different fields of technology in 
their patent regime.  
India implemented the agreement, excluding 
certain types of chemical entities such as polymorphs 
and salts and combination of drugs from patentability. 
The exclusions were made keeping in mind the cost 
and access to healthcare in the country and prevent 
large pharmaceutical companies from making drugs 
inaccessible to the general population who do not 
have the financial strength to meet their health care 
needs. It is important to note the absence of a 
government funded comprehensive health care facility 
in the country. 
The implementation of the agreement, led to a 
large spike in patent filings only to stabilize in the last 
3-4 years. Although, the exclusion of second use and 
polymorphs and salts did result in the industry voicing 
its concern, this did not in any way hamper the filing 
of new applications. 
Indian pharmaceutical patents 
Indian pharmaceutical industry is the third largest 
in the world consisting largely of generic 
pharmaceutical companies. The companies or 
individuals who create or develop new molecules or 
biological entities for treating medical conditions are 
known as innovator companies while those that enter 
the market with improved process or modified dosage 
regimens once the product patent has expired are 
known as generic manufacturers. The advantage of 
generic drug is its competitive pricing generally 
attributed to lower investments in the development 
phase. A generic pharmaceutical product goes through 
an abridged approval process in most countries and 
hence is developed at a lower cost to the company. 
The Rs. 1,50,000 crore worth pharmaceuticals 
industry is currently one of the most robust sectors in 
the country2 catering to both domestic and most of the 
world markets. Although India’s adoption of product 
patent regime in 2005 for the pharmaceutical industry 
in order to be compliant with WTO agreement on 
Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) has given relatively more prominence to 
foreign drug companies in new and innovative drug 
development, the market is still largely controlled by 
local companies with their proven capabilities in 
generic drugs.  
The pharmaceutical industry in India has grown 
from USD 6 billion in 2005 to USD 30 billion in 2015 
and is expected to go up to USD 55 billion by 20203. 
The cost of production in India is significantly lower 
than that in USA and Europe which bestows India 
with a significant advantage. The generic industry in 
India is the largest component in the sector and 
 
Fig. 3—Patents filed and granted worldwide - 1997-2015 
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accounts for about 70% of the products. Indian 
companies export the generic drugs to several 
developing nations across Eastern Europe, Africa, 
Latin America and Asia. They also market and sell 
their products in regulate economies such as North 
America and Western Europe. 
According to a recent report, patented drugs form 
only 9% of drug revenues generated in India3. 
However, the focus on process patents is considerably 
high among generic manufacturers and so are the 
investments in intellectual property (specifically 
patents).  
Patent filing and publication 
According to WIPO Statistics Database, 
pharmaceutical patents are the second largest subject 
matter protected in the patent applications filed in 
India4 as depicted is Figure 4.  
A classification code based search was carried out 
in Thomson Innovation database to understand the 
trend in patent applications filed in India. The 
International Patent Classification (IPC) code 
published by WIPO was used and the code A61K that 
encompasses the pharmaceutical industry was chosen 
to understand the trends. Table 3 shows the filing 
trends in the last two decades. 
An analysis of patent applicants in the last two 
decades highlight the fact that it is dominated by 
multinationals with few Indian companies among the 
top applicants. However, more Indian applicants are 
appearing on the list in the last decade indicating that 
more Indian companies are focusing on research and 
its protection by way of patents. 
The patent filing data shows an upward trend 
during the period 1997-2006 and displaying a distinct 
jump about 2005 when India enacted the law that 
allowed product patents. 
However, post the initial spike in filing, the patent 
filing trend has stabilized in the last 3-4 years and a 
growth though predicted is not expected to be large 
but steady in nature.  
A visual map of technologies or claims of the 
patents filed in India during the last decade from 2007 
was created using the Themescape tool available in 
Thomson Innovation (Fig. 7). It is interesting to note 
Table 3—Patent Applications filed under A61K in India 
Period Number of 
Patents filed 
Number of  
Patents published 
1997-2006 34,132 12,835 
2007-2016 55,135 77,657 
 
 
Fig. 4—Patent filing trends in India based on technology 
(Source: Statistical country profiles-India: WIPO statistics database, 2016) 
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that most patents covered were filed to protect 
applications, formulations and devices. This reaffirms 
the finding that there is limited new drugs or chemical 
entities in the pipeline. The patent landscape also 
revealed the nature of the Indian industry that focused 
on short term gains via new and improved processes,  
 
new formulations and dosage regimens rather than  
 
new molecules. It is significant that certain classes of  
 
drugs targeting certain disease conditions are of  
 
significant interest to the industry and resulted in  
 
more research and hence more number of patents. 
 
Fig. 5—Top ten patent applicants - India (1997-2016) 
Source: Thomson Innovation 
(currently Derwent Innovation: http://www.derwentinnovation.com) 
 
 
 
Fig. 6—Patents filed and published in India 1997-2015 
(Source: Thomson Innovation) 
 
1082 
GOKHALE & KANNAN: PATENTING TRENDS IN INDIAN PHARMACEUTICAL INDUSTRY 
 
 
267 
Conclusion 
The Indian pharmaceutical industry contributes 
significantly to the global pharmaceutical industry. 
Although the Indian companies are known for their 
generic and low priced drugs with limited patent 
filings, focus on new drugs and thus an increased 
investment in R&D is a recent trend. The rate of 
patent applications filed from India appears to have a 
downward trend, but this could be a temporary phase. 
The Indian patent applications in the sector are 
expected to grow, with more and more companies 
including the relatively smaller companies, filing 
patent applications. However, it is too early to 
understand the extent of growth and the trend will be 
more visible in the next five to seven years as the 
industry develops greater number of new and 
improved drugs. Based on the observed patent filing 
and publication data, it is clear that there is a scope 
for substantial growth in investment in research and 
development. Indian companies have shown interest 
in inventing new molecules with significant 
therapeutic properties and it would be worthwhile to 
pursue and grow in this area in order to strengthen 
India’s role as an innovation leader in the world of 
medicines and healthcare. 
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